Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Veracyte, Inc. (Nasdaq: VCYT) SEC filings, offering a detailed view into the company’s financial reporting, governance decisions, and key disclosures. Veracyte is a global cancer diagnostics and genomic testing company whose filings reflect its activities in developing and commercializing tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, as well as research platforms like Afirma GRID and Decipher GRID.
Investors can review Veracyte’s periodic reports on Forms 10-K and 10-Q for information about revenue composition, testing volumes, cost structure, and risk factors. Current reports on Form 8-K capture specific events, such as the release of quarterly financial results or shareholder votes. For example, recent 8-K filings describe quarterly earnings press releases and the approval of amendments to the company’s equity incentive plan, along with voting outcomes at the annual meeting of stockholders.
These filings also discuss Veracyte’s use of non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA margin, and explain which items are excluded from these metrics, such as amortization of acquired intangible assets, acquisition-related expenses, stock-based compensation, and certain restructuring costs. This context helps readers understand how management evaluates the company’s performance relative to GAAP results.
On Stock Titan, Veracyte filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight the main points of lengthy documents, helping users quickly identify key topics such as revenue trends, test portfolio updates, equity plan changes, and shareholder voting results. Users can also monitor forms that may relate to insider activity and executive compensation through the company’s proxy and related disclosures, using the AI tools to navigate complex regulatory language more efficiently.
Veracyte, Inc. Chief Executive Officer Marc Stapley sold 45,523 shares of common stock on March 4, 2026 in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. The trades occurred at weighted average prices of $35.5553 and $36.2787 per share. Following these sales, he directly owns 357,554 Veracyte shares.
VERACYTE, INC. Chief Commercial Officer-CLIA John Leite reported an open-market sale of common stock under a pre-arranged Rule 10b5-1 trading plan. On March 4, 2026, he sold 5,260 shares at a weighted average price of $35.1868 per share, with individual sale prices ranging from $35.00 to $35.53. After this transaction, he continued to hold 107,580 shares of Veracyte common stock directly.
VERACYTE, INC. senior vice president and general counsel Annie McGuire reported selling 6,658 shares of common stock in open-market transactions on March 4, 2026. The sales were made under a Rule 10b5-1 trading plan adopted on August 29, 2025.
The reported weighted average sale prices were $35.2936 per share for 4,994 shares and $36.3393 per share for 1,664 shares. After these sales, McGuire directly owned 94,706 shares of Veracyte common stock.
VCYT files a notice of a proposed affiliate sale of 6,658 Restricted Stock Units. The filing lists the securities to be sold as Common — Restricted Stock Units with an effective date of 03/02/2026. The excerpt also shows a prior 10b5-1 sale of 10,739 common shares on 12/16/2025 attributed to Ann McGuire and identifies Morgan Stanley Smith Barney LLC as the broker.
Marc Stapley reported a sale of 15,000 common shares on 01/22/2026, with proceeds shown as $1,915,576.23. The filing also lists intended issuer-side units: 34,398 Performance Stock Units dated 02/26/202611,125 Restricted Stock Units dated 03/02/2026
The transactions are reported on a Form 144 and the sale was routed through Morgan Stanley Smith Barney LLC on the NASDAQ market.
Veracyte, Inc. senior vice president and general counsel Annie McGuire reported a tax-related share disposition tied to restricted stock units. On March 2, 2026, 6,902 shares of common stock at $36.01 per share were withheld to cover tax obligations in connection with RSU vesting and did not represent a sale. After this withholding, she directly owned 101,364 shares of Veracyte common stock.
VERACYTE, INC. executive Jonathan Wygant, the VP and Chief Accounting Officer, reported a tax-related share disposition. On March 2, 2026, 3,006 shares of common stock were withheld at $36.01 per share to cover tax obligations from vesting restricted stock units, and the footnote states this does not represent a sale. Following this withholding, he directly holds 34,909 shares of Veracyte common stock, including 495 shares purchased on January 31, 2026 through the company’s Employee Stock Purchase Plan.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported a Form 4 transaction involving company common stock. On March 2, 2026, 7,234 shares were withheld at a price of $36.01 per share to cover tax obligations tied to vesting restricted stock units and, as the disclosure notes, this does not represent a sale. After this tax-withholding disposition, Chambers directly owns 149,537 shares of Veracyte common stock.